SCHEMBL709233

SCHEMBL709233

O=C(O)CCc1ccccc1-c1ccc(CN(CCCc2ccccc2)C(=O)c2cc(Cl)ccc2Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 14/20 0.64
PTGER1 P34995 1/20 0.49
PTGER4 P35408 1/20 0.49
PTGER3 P43115 1/20 0.49
PTGER2 P43116 1/20 0.49
FFAR1 O14842 2/20 0.48
FFAR4 Q5NUL3 2/20 0.48
LTB4R2 Q9NPC1 2/20 0.47
LPAR2 Q9HBW0 1/20 0.45
C5AR1 P21730 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708961 0.91 LPAR1 (0.64) LPAR1LTB4R2LPAR2C5AR1
SCHEMBL709398 0.86 LPAR1 (0.72) LPAR1LTB4R2LPAR2
SCHEMBL706827 0.83 LPAR1 (0.63) LPAR1LTB4R2LPAR2
SCHEMBL710059 0.81 LPAR1 (0.62) LPAR1LTB4R2LPAR2
SCHEMBL709709 0.80 LPAR1 (0.72) LPAR1LPAR2
SCHEMBL709026 0.79 LPAR1 (0.73) LPAR1LPAR2
SCHEMBL709668 0.79 LPAR1 (0.75) LPAR1LTB4R2LPAR2
SCHEMBL706855 0.78 LPAR1 (1.00) LPAR1FFAR1FFAR4LPAR2
SCHEMBL704718 0.78 LPAR1 (0.72) LPAR1LTB4R2
SCHEMBL4081027 0.78 LPAR1 (0.53) LPAR1LPAR2C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553075-B1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2013-08-14 EP disclosed
EP-2565178-A1 LPA Receptor Antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2013-03-06 EP disclosed
US-20120088782-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-12 US disclosed
US-8124645-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2012-02-28 US disclosed
US-7820682-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-26 US disclosed
US-20100249157-A2 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-20080293764-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. 2008-11-27 US disclosed
US-20060148830-A1 Lpa receptor antagonist ONO PHARMACEUTICAL CO., LTD. 2006-07-06 US disclosed
EP-1553075-A1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293764-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885PTGER1 353/4885PTGER4 824/4885
US-20100249157-A2 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885PTGER1 353/4885PTGER4 824/4885
US-20120088782-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885PTGER1 353/4885PTGER4 824/4885
US-20060148830-A1 Lpa receptor antagonist LPAR1, LPAR2, LPAR4 LPAR1 1/4885PTGER1 353/4885PTGER4 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.